 |
5 Diseases |  |
67 Trials |
|
67 Trials |  |
4266 News |  |
| «12...52535455565758596061626364» |
- Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change, Trial withdrawal, Trial primary completion date: TAILWIND: Comparison of the Effectiveness of Brexpiprazole With That of Risperidone (clinicaltrials.gov) - Aug 1, 2016
P3, N=0, Withdrawn, Sponsor: H. Lundbeck A/S
N=428 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Jun 2016
- || aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
Trial primary completion date: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (clinicaltrials.gov) - Jul 19, 2016
P1, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
N=428 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Jun 2016 Trial primary completion date: May 2016 --> Sep 2016
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Clinical data, New trial: Striatal Connectivity and Clinical Outcome in Psychosis (clinicaltrials.gov) - Jul 5, 2016
P=N/A, N=170, Not yet recruiting, Sponsor: Northwell Health
- ||||| Caplyta (lumateperone) - Intra / Cellular Therapies
Enrollment closed, Enrollment change, Trial primary completion date: A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (clinicaltrials.gov) - Jul 1, 2016
P3, N=696, Active, not recruiting, Sponsor: Intra-Cellular Therapies, Inc.
Trial primary completion date: May 2016 --> Sep 2016 Recruiting --> Active, not recruiting | N=580 --> 696 | Trial primary completion date: May 2016 --> Aug 2016
- ||| asenapine / Generic mfg.
Enrollment open: An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308) (clinicaltrials.gov) - May 31, 2016
P=N/A, N=3000, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | N=580 --> 696 | Trial primary completion date: May 2016 --> Aug 2016 Active, not recruiting --> Recruiting
- ||| aripiprazole / Generic mfg.
Trial completion, Trial primary completion date: Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (clinicaltrials.gov) - May 25, 2016
P=N/A, N=83, Completed, Sponsor: University of British Columbia
Active, not recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Feb 2016
- |||||||||| risperidone controlled-release implant (BB-0817) / Braeburn
New P3 trial: Safety and Tolerability of Risperidone Implants (clinicaltrials.gov) - May 16, 2016
P3, N=100, Recruiting, Sponsor: Braeburn Pharmaceuticals
- | risperidone controlled-release implant (BB-0817) / Braeburn
Enrollment change, Trial primary completion date: Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant (clinicaltrials.gov) - May 13, 2016
P2, N=50, Recruiting, Sponsor: Braeburn Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Feb 2016 N=20 --> 50 | Trial primary completion date: Dec 2016 --> Jun 2017
- risperidone / Generic mfg.
Enrollment open: Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia (clinicaltrials.gov) - May 12, 2016
P=N/A, N=30, Recruiting, Sponsor: Northwell Health
N=20 --> 50 | Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: TAILWIND: Comparison of the Effectiveness of Brexpiprazole With That of Risperidone (clinicaltrials.gov) - May 2, 2016
P3, N=428, Not yet recruiting, Sponsor: H. Lundbeck A/S
- Trial completion, Enrollment change, Trial primary completion date: A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry (clinicaltrials.gov) - Apr 11, 2016
P2, N=9, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=155 --> 9 | Trial primary completion date: Apr 2016 --> Jan 2016
- clozapine / Generic mfg.
Trial primary completion date: CLOCS: Clozapine for Cannabis Use in Schizophrenia (clinicaltrials.gov) - Apr 1, 2016
P4, N=132, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Active, not recruiting --> Completed | N=155 --> 9 | Trial primary completion date: Apr 2016 --> Jan 2016 Trial primary completion date: Sep 2017 --> Dec 2017
- risperidone / Generic mfg.
Enrollment closed: Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=25, Active, not recruiting, Sponsor: Northwell Health
Trial primary completion date: Sep 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- |||||||||| Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
New P3 trial: DayBreak: Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (clinicaltrials.gov) - Mar 23, 2016
P3, N=964, Recruiting, Sponsor: H. Lundbeck A/S
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Biomarker, Trial completion, Phase classification, Enrollment change, Trial primary completion date: Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) (clinicaltrials.gov) - Mar 17, 2016
P4, N=82, Completed, Sponsor: Medical University of South Carolina
Recruiting --> Active, not recruiting Recruiting --> Completed | Phase classification: PN/A --> P4 | N=250 --> 82 | Trial primary completion date: Jan 2015 --> Aug 2015
- Clopixol (zuclopenthixol) / Lundbeck, Serlect (sertindole) / Lundbeck, Abbott
Enrollment closed, Trial primary completion date: Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (clinicaltrials.gov) - Mar 1, 2016
P4, N=25, Active, not recruiting, Sponsor: Technische Universität München
Recruiting --> Completed | Phase classification: PN/A --> P4 | N=250 --> 82 | Trial primary completion date: Jan 2015 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2016
- || risperidone / Generic mfg., quetiapine / Generic mfg.
Trial completion: Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients (clinicaltrials.gov) - Feb 27, 2016
P3, N=30, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2016 Active, not recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: Investigate Risperidone for the Treatment of Schizophrenia in Adolescents (clinicaltrials.gov) - Feb 27, 2016
P3, N=160, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Recruiting --> Completed
- || risperidone / Generic mfg.
Trial completion: Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents (clinicaltrials.gov) - Feb 27, 2016
P3, N=13, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion, Monotherapy: A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression (clinicaltrials.gov) - Feb 27, 2016
P3, N=258, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 27, 2016
P3, N=473, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=279, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy. (clinicaltrials.gov) - Feb 27, 2016
P3, N=301, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed No longer recruiting --> Completed
- risperidone / Generic mfg.
Trial primary completion date: VCFS: The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (clinicaltrials.gov) - Jan 30, 2016
P4, N=400, Recruiting, Sponsor: The Chaim Sheba Medical Center
No longer recruiting --> Completed Trial primary completion date: Dec 2012 --> Dec 2020
- || Arvisol (cannabidiol) / Echo Pharma
Preclinical, Trial primary completion date: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Jan 22, 2016
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Trial primary completion date: Dec 2012 --> Dec 2020 Trial primary completion date: Oct 2015 --> Oct 2016
- risperidone / Generic mfg.
New trial: Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: North Shore Long Island Jewish Health System
- clozapine / Generic mfg.
Trial primary completion date: CLOCS: Clozapine for Cannabis Use in Schizophrenia (clinicaltrials.gov) - Jan 22, 2016
P4, N=132, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Oct 2016 --> Sep 2017
- | risperidone controlled-release implant (BB-0817) / Braeburn
New P2 trial: Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant (clinicaltrials.gov) - Jan 19, 2016
P2, N=20, Recruiting, Sponsor: Braeburn Pharmaceuticals
- risperidone / Generic mfg.
Trial primary completion date: ProjectV: Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior (clinicaltrials.gov) - Jan 18, 2016
P2, N=52, Recruiting, Sponsor: University of California, Los Angeles
Trial primary completion date: Oct 2016 --> Sep 2017 Trial primary completion date: Sep 2013 --> Sep 2016
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Trial completion: Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis (clinicaltrials.gov) - Jan 12, 2016
P4, N=198, Completed, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Sep 2013 --> Sep 2016 Active, not recruiting --> Completed
- | New P1/2 trial: The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment (clinicaltrials.gov) - Jan 11, 2016
P1/2, N=200, Recruiting, Sponsor: Shanxi Medical University
- ||| Enrollment closed: A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry (clinicaltrials.gov) - Dec 21, 2015
P2, N=155, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
New P4 trial: A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia (clinicaltrials.gov) - Dec 18, 2015
P4, N=90, Recruiting, Sponsor: Alkermes, Inc.
- ||| aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
New P1 trial: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (clinicaltrials.gov) - Dec 18, 2015
P1, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Risperdal Consta (risperidone depot formulation) / J&J
Trial completion, Trial primary completion date: Switching From Consta® to Sustenna® in Patients With Schizophrenia (clinicaltrials.gov) - Dec 9, 2015
P=N/A, N=50, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Mar 2014 --> May 2015
- || aripiprazole / Generic mfg.
Trial primary completion date: Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=90, Recruiting, Sponsor: University of British Columbia
Recruiting --> Completed | Trial primary completion date: Mar 2014 --> May 2015 Trial primary completion date: Sep 2015 --> Sep 2016
- risperidone / Generic mfg.
Phase classification: Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar (clinicaltrials.gov) - Nov 9, 2015
P3, N=65, Completed, Sponsor: University of Illinois at Chicago
Trial primary completion date: Sep 2015 --> Sep 2016 Phase classification: P2/3 --> P3
- ||||| New trial: Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (clinicaltrials.gov) - Nov 9, 2015
P4, N=300, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
- | New P4 trial: JFR: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana (clinicaltrials.gov) - Nov 2, 2015
P4, N=139, Completed, Sponsor: University of Ghana Medical School
- risperidone / Generic mfg., trazodone ER / Generic mfg.
Enrollment change, Trial termination, Combination therapy, Monotherapy: Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium (clinicaltrials.gov) - Oct 29, 2015
P4, N=5, Terminated, Sponsor: Rochester General Hospital
Phase classification: P2/3 --> P3 N=128 --> 5 | Recruiting --> Terminated; Lack of enrollment
- risperidone / Generic mfg.
New trial, Adherence: ACER: Guideline vs Usual Treatment in Schizophrenic Adolescents (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=91, Completed, Sponsor: Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
- Clopixol (zuclopenthixol) / Lundbeck
New trial: Antipsychotics and Risk of Hyperglycemic Emergencies (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=725489, Completed, Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
- | risperidone / Generic mfg.
New P4 trial: off-label use of risperidone in people with intellectual disability: A discontinuation study Off-label gebruik van risperidon door mensen met een verstandelijke beperking: een afbouwstudie (EUDRACT) - Oct 7, 2015
P4, N=120, Ongoing, Sponsor: UMCG
- | New P4 trial: Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder (clinicaltrials.gov) - Sep 29, 2015
P4, N=54, Not yet recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
- risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Trial termination: A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (clinicaltrials.gov) - Sep 28, 2015
P4, N=17, Terminated, Sponsor: Johnson & Johnson Taiwan Ltd
N=128 --> 5 | Recruiting --> Terminated; Lack of enrollment Active, not recruiting --> Terminated; The study was terminated due to insufficient sample size and protocol compliance issue.
- risperidone / Generic mfg.
Trial primary completion date: Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=25, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Active, not recruiting --> Terminated; The study was terminated due to insufficient sample size and protocol compliance issue. Trial primary completion date: Jul 2015 --> Jul 2016
- | New P1/2 trial: Nicotinic Receptors and Schizophrenia (clinicaltrials.gov) - Sep 2, 2015
P1/2, N=60, Recruiting, Sponsor: University of Colorado, Denver
- Enrollment closed: Omega-3 Dietary Supplements in Schizophrenia (clinicaltrials.gov) - Sep 2, 2015
P=N/A, N=58, Active, not recruiting, Sponsor: Delbert Robinson
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting
- risperidone / Generic mfg.
New P1/2 trial: Schizotypal Personality Disorder Risperidone (clinicaltrials.gov) - Aug 28, 2015
P1/2, N=21, Completed, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- | aripiprazole / Generic mfg., risperidone / Generic mfg.
New P4 trial: PAFIP3_1Y: Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up (clinicaltrials.gov) - Aug 25, 2015
P4, N=200, Recruiting, Sponsor: Fundaci